Use of compounded hormone therapy in the United States: report of The North American Menopause Society Survey. Issue 12 (December 2015)

• Record Type: Journal Article
• Authors: Gass, Margery L.S.; Stuenkel, Cynthia A.; Utian, Wulf H.; LaCroix, Andrea; Liu, James H.; Shifren, Jan L.
• Is Part Of: Menopause. Volume 22:Issue 12(2015)
• Publication Date: 2015-12
• Subjects: Bioidentical -- Compounded hormone therapy -- FDA -- Testosterone; Menopause -- Periodicals; 618.175005
• DOI: 10.1097/GME.0000000000000553
• Languages: English
• ISSNs: 1072-3714

Abstract

Abstract: Objective: A national survey was conducted to determine the extent of use of compounded hormone therapy (C-HT) and to characterize the differences between C-HT users and users of hormone therapy approved by the US Food and Drug Administration (FDA-HT users). Methods: This Internet survey enrolled 3, 725 women aged 40 to 84 years who were postmenopausal or experiencing the menopause transition. The sample was weighted slightly by age, region, education, and race to reflect population attributes based on US Census data. Results: Overall, 9% of women were current users of HT, and 28% of all respondents were ever-users of HT. C-HT users represented 31% of ever-users of HT, 35% of current users of HT, and 41% of ever-users aged 40 to 49 years. Approximately 13% of ever-users indicated current or past use of testosterone. The most cited reason for using HT was vasomotor symptoms (∼70%). Nonapproved indications for using HT were selected more often by C-HT users. There were four reports of endometrial cancer among the 326 C-HT users compared with none reported among the 738 FDA-HT users. Significance was not determined because of small numbers. Conclusions: This survey indicates substantial use of C-HT across the country and the possibility of higher rates of endometrial side effects with such products. There is a need for standardized data collection on the extent of use of compounded hormones and their potential risks.